Sichenzia Ross Friedman Ference LLP Represents Rodman & Renshaw in Public Offering of Skystar Bio-Pharmaceutical
NEW YORK, NEW YORK—July 7, 2009—Sichenzia Ross Friedman Ference LLP, a leading securities law firm specializing in micro, small and mid-cap public companies, today announced their successful representation of Rodman & Renshaw, LLC in an underwritten public offering of Skystar Bio Pharmaceutical Co., Ltd. (NASDAQ:SKBI). The offering consists of 1,400,000 shares of common stock at a price of $12.98 per share and an over-allotment option of an additional 210,000 shares. The total offering amount was 20,897,000. The offering closed today, July 7, 2009. This offering “demonstrates the ability for investment bankers and investors to uncover inherent value in China-based companies whose market capitalization has been undervalued in this economic climate,” said Gregory Sichenzia, Principal at Sichenzia Ross Friedman Ference. “This transaction represents a new financing model for small and mid-cap companies to gain access to and leverage US capital markets. We believe this innovative model enables companies with diminished share prices and strong earnings to recapitalize, list on senior exchanges and ultimately raise capital.” Skystar is a China-based developer and distributor of veterinary healthcare and medical care products. The Company has four product lines (veterinary medicines, micro-organisms, vaccines and feed additives), approximately 170 products, and over 40 new products in the developmental stage. Skystar has formed strategic sales distribution networks covering 29 provinces throughout the China region. Rodman & Renshaw, LLC, a subsidiary of Rodman & Renshaw Capital Group, Inc.(NASDAQ:RODM) served as sole book-running manager for the offering.
About Sichenzia Ross Friedman Ference LLP
Sichenzia Ross Friedman Ference LLP (SRFF) has led the nation in representing public companies in private financing transactions since 2004. The New York based firm has completed over 250 such transactions totaling over 1 billion dollars. The Firm has also represented many companies and underwriters in public offerings of securities. The firm’s clients include private and public corporations, partnerships, broker-dealers, bank-affiliated broker-dealers, investment advisors, registered personnel, public and corporate customers and investors, partnerships and other entities. SRFF also maintains specialized Asian and Israeli corporate practice groups. For more information visit, www.srff.com.
For media inquiries please contact: